Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: Results from a randomized, double-blind, vehicle-controlled study

Pediatrics

Volumn 116, Issue 3, 2005, Pages

  Schachner, Lawrence A ^a,h   Lamerson, Cindy ^b   Sheehan, Mary P ^c   Boguniewicz, Mark ^d   Mosser, Joy ^e   Raimer, Sharon ^f   Shull, Toni ^g   Jaracz, Eileen ^g  

^a UNIVERSITY OF MIAMI   (United States)

^b Nevada Center for Dermatology   (United States)

^c Fox Chappell Dermatology   (United States)

^d Children's Hospital Colorado   (United States)

^e Central Ohio Skin and Cancer Inc   (United States)

^f University of Texas Medical Branch School of Medicine   (United States)

^g ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Atopic dermatitis; Pediatrics; Tacrolimus ointment; Topical immunomodulatory agents

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DRUG VEHICLE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ACNE; ADOLESCENT; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE FOLLICULITIS; APPLICATION SITE INFECTION; APPLICATION SITE PAIN; APPLICATION SITE PRURITUS; ARTICLE; ATOPIC DERMATITIS; BODY SURFACE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; ECZEMA; FEMALE; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLLUSCUM CONTAGIOSUM; MONOTHERAPY; MULTICENTER STUDY; OINTMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERRUCA VULGARIS; PATHOLOGY; PRESCHOOL CHILD; TOPICAL DRUG ADMINISTRATION; VEHICLES;

ADMINISTRATION, TOPICAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DOUBLE-BLIND METHOD; HUMANS; IMMUNOSUPPRESSIVE AGENTS; OINTMENTS; TACROLIMUS; VEHICLES;

EID: 31544483145     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-2638     Document Type: Article

References (31)

1. Hanifin JM, Cooper KD, Ho VC, et al. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence-Based Clinical Practice Guidelines." J Am Acad Dermatol. 2004;50:391-404
2. National Institutes of Health, US Department of Health and Human Services. Handout on health: atopic dermatitis. NIH publication 03-4272. 1999. Available at: www.niams.nih.gov.hi.topics/dermatitis/index.html#link_a. Accessed July 26, 2005
3. Laughter D, Istvan JA, Tofte SJ, Hanifin JM. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 2000;43:649-655
4. Bender BG, Leung SB, Leung DYM. Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure. J Allergy Clin Immunol. 2003;111:598-602
5. Ben-Gashir MA, Seed PT, Hay RJ. Are quality of family life and disease severity related in childhood atopic dermatitis? J Eur Acad Dermatol Venereol. 2002;16:455-462
6. Paller AS, McAlister RO, Doyle JJ, Jackson A. Perceptions of physicians and pediatric patients about atopic dermatitis, its impact, and its treatment. Clin Pediatr (Phila). 2002;41:323-332
7. Drake L, Prendergast M, Maher R, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001;44:S65-S72
8. Chamlin SL, Frieden IJ, Williams ML, Chren M. Effects of atopic dermatitis on young American children and their families. Pediatrics. 2004;114:607-611
9. Kemp AS. Cost of illness of atopic dermatitis in children: a societal perspective. Pharmacoeconomics. 2003;21:105-113
10. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: its impact on the family and financial cost. Arch Dis Child. 1997;76:159-162
11. Castanedo-Cazares JP, Lopez-Lucio RH, Moncada B. Cushing syndrome following the prescription of antifungal, antibiotic, corticosteroid cream. Int J Dermatol. 2003;42:318
12. Ermis B, Ors R, Tastekin A, Ozkan B. Cushing's syndrome secondary to topical corticosteroids abuse. Clin Endocrinol (Oxf). 2003;58:795-796
13. Aalto-Korte K, Turpeinen M. Bone mineral density in patients with atopic dermatitis. Br J Dermatol. 1997;136(2):172-175
14. Walker BR, Best R, Shackleton CHL, Padfield LP, Edwards CRW. Increased vasoconstrictor sensitivity to glucocorticoids in essential hypertension. Hypertension. 1996;27:190-196
15. Hoare C, Li Wan Po A, Williams H. Systematic review of treatments of atopic eczema. Health Technol Assess. 2000;4(37):1-191
16. Alaiti S, Kang S, Fiedler VC, et al. Tacrolimus (FK506) ointment for atopic dermatitis: a phase I study in adults and children. J Am Acad Dermatol. 1998;38:69-76
17. Harper J, Smith C, Rubins A, et al. A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis. J Invest Dermatol. 2005;124:695-699
18. Kapp A, Allen BR, Reitamo S. Atopic dermatitis management with tacrolimus ointment (Protopic). J Dermatolog Treat. 2003;14(suppl 1):5-16
19. Rubins A, Gutmane R, Valdmane N, Stevenson P, Foster C, Undre N. Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis. J Invest Dermatol. 2005;125:68-71
20. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus Ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol. 1998;111:396-398
21. Kyllönen H, Remitz A, Mandelin JM, Elg P, Reitamo S. Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis. Br J Dermatol. 2004;150:1174-1181
22. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:S58-S64
23. Paller A, Eichenfield LF, Leung DYM, Stewart D, Appell M. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001;44:S47-S57
24. Reitamo S, Van Leent EJM, Ho V, et al. Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis. J Allergy Clin Immunol. 2002;109:539-546
25. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol. 1998;102:637-644
26. Reitamo S, Harper J, Bos JD, et al. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial. Br J Dermatol. 2004;150:554-562
27. Hanifin JM, Leung DYM, Paller A, Rico J. Tacrolimus ointment monotherapy is safe and effective for the long-term treatment (more than 3 years) of atopic dermatitis in pediatric patients [abstract]. J Allergy Clin Immunol. 2003;111(2):S130
28. Hanifin JM, Rajika G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-47
29. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11-18
30. Lawrence I. Three studies in pediatric and adult patients demonstrate that tacrolimus ointment is safe and effective in the treatment of atopic dermatitis. Acta Dermatovenerol Croat. 2003;11(2):126-132
31. Loden M. The skin barrier and use of moisturizers in atopic dermatitis. Clin Dermatol. 2003;21:145-57